Skip to main content

Advertisement

Table 1 Baseline demographic characteristics of study participants

From: The safety and efficacy of prednisolone in preventing reaccumulation of ascites among endomyocardial fibrosis patients in Uganda: a randomized clinical trial

Characteristic Prednisolone, n (%) Placebo, n (%) P value
Mean age 27.947 (SD 9.50) 27.125 (SD 8.82) 0.709
Sex    1.000
 Male 5 (36.84) 7 (31.25)  
 Female 11 (68.75) 12 (63.16)  
Level of education    0.491
 No formal education 2 (12.50) 4 (21.05)  
 Primary 12 (75.00) 10 (52.63)  
 Secondary 2 (12.50) 5 (26.32)  
Occupation    0.636
 Unemployed 11 (68.75) 13 (68.42)  
 Employed 5 (31.25) 6 (31.58)  
Duration of disease    0.529
 <1 year 13 (81.25) 11 (57.89)  
 1–2 years 1 (6.25) 1 (5.26)  
 3–5 years 1 (6.25) 3 (15.79)  
 >5 years 1 (6.25) 4 (21.05)  
Family history of EMF    0.398
 Yes 4 (25.00) 3 (15.795)  
 No 12 (75.00) 16 (84.21)  
Paracentesis in prior 3 months    0.763
 None 6 (37.50) 8 (42.11)  
 Once 1 (6.25) 3 (15.79)  
 Twice 4 (25.00) 4 (21.05)  
 Thrice 3 (18.75) 1 (5.26)  
 More than 3 times 2 (12.50) 3 (15.79)  
Mean weight 47.894 (SD 10.32) 45.625 (SD 15.56) 0.703
Blood pressure    0.234
 <90/60 0 (0.00) 3 (15.79)  
 90/60–139/89 16 (100.00) 16 (84.21)  
Temperature    0.457
 <35 1 (6.25) 0 (0.00)  
 35–37.5 15 (93.75) 19 (100.00)  
Random blood sugar    0.481
 <4 mmol/dl 4 (25) 6 (31.58)  
 4–11 mmol/dl 12 (75.00) 13 (68.42)  
White cell count (WBC)    0.758
 >10,000 1 (8.33) 1 (5.88)  
 4000–10,000 7 (58.33) 8 (47.06)  
 <4000 4 (33.33) 8 (47.06)  
Eosinophilia (>10 % WBC) 2 (16.67) 1 (5.88) 0.348
Haemoglobin    0.793
 >14 mg/dl 9 (75.00) 12 (70.59)  
 12–14 mg/dl 3 (25.00) 5 (29.41)  
SAAG    0.414
 <1.1 1 (8.33) 0 (0.00)  
 >1.1 11 (91.67) 17 (100)  
Ascitic fluid lymphocytes    0.091
 >40 % 15 (93.75) 13 (68.42)  
 <40 % 1 (6.25) 6 (31.58)